Steffen Boettcher

This study shows that Tet2-mutant clonal hematopoiesis promotes while Dnmt3a-mutant clonal hematopoiesis inhibits breast cancer progression with age, identifying IL-1/CXCL2 inflammation as a therapeutic target.

This study identifies how RNA splicing factor mutations drive myeloid neoplasm by disrupting proteomic networks through mis-splicing, validated via single-cell transcriptomics and proteomics.

The paper develops a mathematical model and Bayesian framework to evaluate CAR T-cell efficacy against AML, revealing antigen-specific resistance mechanisms.

This study shows that DTP cells in EGFR-mutant lung cancer drive immunosuppression through YAP/TEAD activity, and co-targeting YAP/TEAD improves EGFR TKI therapy efficacy.

This study identifies recurrent ERBB4 mutations with oncogenic potential and resistance to targeted therapies, suggesting clinical implications for treatment strategies.

This study identifies GGPP, a mevalonate pathway byproduct, as critical for chemoresistance in TP53mut AML through ROS regulation and mitochondria stress response, suggesting statin-based therapies could be effective.

This paper identifies a novel MYC-GSPT1 feedback loop and reports a dual degrader, GT19630, that effectively targets MYC-driven cancers with anti-proliferative and apoptotic effects.

This study identifies circulating senescent myeloid cells as drivers of blood-brain barrier breakdown and neurodegeneration in LCH-ND.